Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Last trade$38.93
Day change-$0.335 (-0.85%)
Day range$38.25 – $39.41
Volume841,360
Market cap$3.86B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$3.86B
Price / earnings
—
Price / book
3.37×
Price / sales
—
EV / sales
—
EV / EBITDA
-8.16×
Profitability
Earnings per share
-$4.36
Return on assets
-35.73%
Return on equity
-37.4%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
21.19×
Quick ratio
21.19×
Cash ratio
1.82×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$357.11M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for XENE, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$7.5M
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$7.5M
$0
Selling, general and administrative
$24.42M
$23.93M
$23.82M
$22.07M
$19.28M
$19.24M
$19.04M
$18.01M
Research and development
$95.65M
$99.22M
$88.51M
$87.7M
$77.05M
$74.99M
$61.2M
$59.47M
Total operating expenses
$120.07M
$123.16M
$112.33M
$109.77M
$96.34M
$94.23M
$80.24M
$77.48M
Operating income
-$120.07M
-$123.16M
-$112.33M
-$109.77M
-$96.34M
-$94.23M
-$72.74M
-$77.48M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$108.59M
-$111.32M
-$104.87M
-$104.72M
-$90.22M
-$85.33M
-$64.62M
-$69.53M
Income taxes
$1.84M
-$585K
-$2.57M
$538K
$677K
-$626K
$427K
-$3.85M
Net income
-$110.44M
-$110.74M
-$102.3M
-$105.26M
-$90.9M
-$84.71M
-$65.05M
-$65.69M
Net income attributable to common shareholders
-$110.44M
-$110.74M
-$102.3M
-$105.26M
-$90.9M
-$84.71M
-$65.05M
-$65.69M
EBITDA
-$119.51M
-$122.6M
-$111.74M
-$109.16M
-$95.7M
-$93.6M
-$72.08M
-$76.81M
Basic earnings per share
-$1.11
-$1.11
-$1.17
-$1.31
-$1.15
-$1.07
-$0.83
-$0.84
Diluted earnings per share
-$1.11
-$1.11
-$1.17
-$1.31
-$1.15
-$1.07
-$0.83
-$0.84
Recent news
Company coverage with links to the original publishers.
Wolf Popper LLP is investigating potential securities claims on behalf of Xenon Pharmaceuticals investors following a significant stock price decline. On September 17, 2026, Xenon announced a voluntary pause in new patient enrollment in its MDD and bipolar depression clinical studies due to neuropsychiatric adverse events. The announcement triggered a 30.7% stock price drop, falling from approximately $57.35 to $39.75 per share on heavy trading volume.
Xenon Pharmaceuticals paused enrollment in phase III depression trials for azetukalner after unexpected neurological and psychiatric side effects emerged, including confusion, speech difficulties, and psychosis cases. The company is reviewing dose adjustments with top-line results expected in Q1 2027. However, Xenon's epilepsy program remains promising, with an FDA application pending for focal onset seizures treatment, offering potential growth opportunities despite the depression program setback.
Xenon Pharmaceuticals submitted an FDA application for azetukalner to treat focal onset seizures, supported by positive phase IIb and phase III epilepsy studies showing significant seizure reductions. However, the company temporarily paused enrollment in depression studies due to neuropsychiatric adverse events, causing a 27% stock decline in premarket trading. The X-NOVA2 depression study is 80% enrolled with top-line data expected in Q1 2027.
The metastatic prostate cancer market is projected to experience robust growth through 2036, valued at USD 11.5 billion in 2025 across seven major markets. The market is transitioning from conventional androgen deprivation therapy toward combination-based, biomarker-driven approaches, with novel therapies such as PSMA-targeted radioligand therapies and PARP inhibitors reshaping the treatment paradigm. Key emerging drugs include 225Ac-PSMA-617, 177Lu-DOTA-rosopatamab, and cabozantinib, with multiple pharmaceutical companies advancing innovative treatments in clinical trials.
Xenon Pharmaceuticals announced positive Phase 3 X-TOLE2 study results for azetukalner, a KV7 potassium channel opener for focal onset seizures, showing 53.2% reduction in monthly seizure frequency at 25mg versus 10.4% for placebo. Long-term data from the 48-month X-TOLE open-label extension study demonstrated nearly 40% of participants achieved at least 12 months of seizure freedom. The company plans to submit a New Drug Application to the FDA in Q3 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.